Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 39

  • Showing results for alphonse ouedraogo. Your search for Alphonse Oudraogo retrieved no results.
1.

Efficacy of Olyset Duo, a bednet containing pyriproxyfen and permethrin, versus a permethrin-only net against clinical malaria in an area with highly pyrethroid-resistant vectors in rural Burkina Faso: a cluster-randomised controlled trial.

Tiono AB, Ouédraogo A, Ouattara D, Bougouma EC, Coulibaly S, Diarra A, Faragher B, Guelbeogo MW, Grisales N, Ouédraogo IN, Ouédraogo ZA, Pinder M, Sanon S, Smith T, Vanobberghen F, Sagnon N, Ranson H, Lindsay SW.

Lancet. 2018 Aug 18;392(10147):569-580. doi: 10.1016/S0140-6736(18)31711-2. Epub 2018 Aug 10. Erratum in: Lancet. 2018 Aug 25;392(10148):636.

PMID:
30104047
2.

Population Pharmacokinetics of the Antimalarial Amodiaquine: a Pooled Analysis To Optimize Dosing.

Ali AM, Penny MA, Smith TA, Workman L, Sasi P, Adjei GO, Aweeka F, Kiechel JR, Jullien V, Rijken MJ, McGready R, Mwesigwa J, Kristensen K, Stepniewska K, Tarning J, Barnes KI, Denti P; WWARN Amodiaquine PK Study Group .

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e02193-17. doi: 10.1128/AAC.02193-17. Print 2018 Oct.

3.

Transmission of molecularly undetectable circulating parasite clones leads to high infection complexity in mosquitoes post feeding.

Grignard L, Gonçalves BP, Early AM, Daniels RF, Tiono AB, Guelbéogo WM, Ouédraogo A, van Veen EM, Lanke K, Diarra A, Nebie I, Sirima SB, Targett GA, Volkman SK, Neafsey DE, Wirth DF, Bousema T, Drakeley C.

Int J Parasitol. 2018 Jul;48(8):671-677. doi: 10.1016/j.ijpara.2018.02.005. Epub 2018 May 5.

4.

Safety of single low-dose primaquine in glucose-6-phosphate dehydrogenase deficient falciparum-infected African males: Two open-label, randomized, safety trials.

Bastiaens GJH, Tiono AB, Okebe J, Pett HE, Coulibaly SA, Gonçalves BP, Affara M, Ouédraogo A, Bougouma EC, Sanou GS, Nébié I, Bradley J, Lanke KHW, Niemi M, Sirima SB, d'Alessandro U, Bousema T, Drakeley C.

PLoS One. 2018 Jan 11;13(1):e0190272. doi: 10.1371/journal.pone.0190272. eCollection 2018.

5.

A randomised, double-blind clinical phase II trial of the efficacy, safety, tolerability and pharmacokinetics of a single dose combination treatment with artefenomel and piperaquine in adults and children with uncomplicated Plasmodium falciparum malaria.

Macintyre F, Adoke Y, Tiono AB, Duong TT, Mombo-Ngoma G, Bouyou-Akotet M, Tinto H, Bassat Q, Issifou S, Adamy M, Demarest H, Duparc S, Leroy D, Laurijssens BE, Biguenet S, Kibuuka A, Tshefu AK, Smith M, Foster C, Leipoldt I, Kremsner PG, Phuc BQ, Ouedraogo A, Ramharter M; OZ-Piperaquine Study Group.

BMC Med. 2017 Oct 9;15(1):181. doi: 10.1186/s12916-017-0940-3.

6.

Antibody responses to P. falciparum blood stage antigens and incidence of clinical malaria in children living in endemic area in Burkina Faso.

Cherif MK, Ouédraogo O, Sanou GS, Diarra A, Ouédraogo A, Tiono A, Cavanagh DR, Michael T, Konaté AT, Watson NL, Sanza M, Dube TJT, Sirima SB, Nebié I.

BMC Res Notes. 2017 Sep 8;10(1):472. doi: 10.1186/s13104-017-2772-9.

7.

Immunogenicity and Safety of 10-valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Administered to Children With Sickle Cell Disease Between 8 Weeks and 2 Years of Age: A Phase III, Open, Controlled Study.

Sirima SB, Tiono A, Gansané Z, Siribié M, Zongo A, Ouédraogo A, François N, Strezova A, Dobbelaere K, Borys D.

Pediatr Infect Dis J. 2017 May;36(5):e136-e150. doi: 10.1097/INF.0000000000001518.

PMID:
28403055
8.

An epidemiological study to assess Plasmodium falciparum parasite prevalence and malaria control measures in Burkina Faso and Senegal.

Diallo A, Sié A, Sirima S, Sylla K, Ndiaye M, Bountogo M, Ouedraogo E, Tine R, Ndiaye A, Coulibaly B, Ouedraogo A, Faye B, Ba EH, Compaore G, Tiono A, Sokhna C, Yé M, Diarra A, Bahmanyar ER, De Boer M, Pirçon JY, Usuf EA.

Malar J. 2017 Feb 6;16(1):63. doi: 10.1186/s12936-017-1715-1.

9.

A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African children.

Sirima SB, Mordmüller B, Milligan P, Ngoa UA, Kironde F, Atuguba F, Tiono AB, Issifou S, Kaddumukasa M, Bangre O, Flach C, Christiansen M, Bang P, Chilengi R, Jepsen S, Kremsner PG, Theisen M; GMZ2 Trial Study Group.

Vaccine. 2016 Aug 31;34(38):4536-4542. doi: 10.1016/j.vaccine.2016.07.041. Epub 2016 Jul 28.

PMID:
27477844
10.

Comparison of artesunate-mefloquine and artemether-lumefantrine fixed-dose combinations for treatment of uncomplicated Plasmodium falciparum malaria in children younger than 5 years in sub-Saharan Africa: a randomised, multicentre, phase 4 trial.

Sirima SB, Ogutu B, Lusingu JPA, Mtoro A, Mrango Z, Ouedraogo A, Yaro JB, Onyango KO, Gesase S, Mnkande E, Ngocho JS, Ackermann I, Aubin F, Vanraes J, Strub N, Carn G.

Lancet Infect Dis. 2016 Oct;16(10):1123-1133. doi: 10.1016/S1473-3099(16)30020-2. Epub 2016 Jul 16.

11.

A Worldwide Map of Plasmodium falciparum K13-Propeller Polymorphisms.

Ménard D, Khim N, Beghain J, Adegnika AA, Shafiul-Alam M, Amodu O, Rahim-Awab G, Barnadas C, Berry A, Boum Y, Bustos MD, Cao J, Chen JH, Collet L, Cui L, Thakur GD, Dieye A, Djallé D, Dorkenoo MA, Eboumbou-Moukoko CE, Espino FE, Fandeur T, Ferreira-da-Cruz MF, Fola AA, Fuehrer HP, Hassan AM, Herrera S, Hongvanthong B, Houzé S, Ibrahim ML, Jahirul-Karim M, Jiang L, Kano S, Ali-Khan W, Khanthavong M, Kremsner PG, Lacerda M, Leang R, Leelawong M, Li M, Lin K, Mazarati JB, Ménard S, Morlais I, Muhindo-Mavoko H, Musset L, Na-Bangchang K, Nambozi M, Niaré K, Noedl H, Ouédraogo JB, Pillai DR, Pradines B, Quang-Phuc B, Ramharter M, Randrianarivelojosia M, Sattabongkot J, Sheikh-Omar A, Silué KD, Sirima SB, Sutherland C, Syafruddin D, Tahar R, Tang LH, Touré OA, Tshibangu-wa-Tshibangu P, Vigan-Womas I, Warsame M, Wini L, Zakeri S, Kim S, Eam R, Berne L, Khean C, Chy S, Ken M, Loch K, Canier L, Duru V, Legrand E, Barale JC, Stokes B, Straimer J, Witkowski B, Fidock DA, Rogier C, Ringwald P, Ariey F, Mercereau-Puijalon O; KARMA Consortium.

N Engl J Med. 2016 Jun 23;374(25):2453-64. doi: 10.1056/NEJMoa1513137.

12.

Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether-lumefantrine in children with asymptomatic infection: a randomised, double-blind, placebo-controlled trial.

Gonçalves BP, Tiono AB, Ouédraogo A, Guelbéogo WM, Bradley J, Nebie I, Siaka D, Lanke K, Eziefula AC, Diarra A, Pett H, Bougouma EC, Sirima SB, Drakeley C, Bousema T.

BMC Med. 2016 Mar 8;14:40. doi: 10.1186/s12916-016-0581-y.

13.

Clinical Variation of Plasmodium falciparum eba-175, ama-1, and msp-3 Genotypes in Young Children Living in a Seasonally High Malaria Transmission Setting in Burkina Faso.

Soulama I, Sermé SS, Bougouma EC, Diarra A, Tiono AB, Ouedraogo A, Konate AT, Nebie I, Sirima SB.

J Parasitol Res. 2015;2015:985651. doi: 10.1155/2015/985651. Epub 2015 Nov 8.

14.

Health providers' perceptions of clinical trials: lessons from Ghana, Kenya and Burkina Faso.

Angwenyi V, Asante KP, Traoré A, Febir LG, Tawiah C, Kwarteng A, Ouédraogo A, Sirima SB, Owusu-Agyei S, Imoukhuede EB, Webster J, Chandramohan D, Molyneux S, Jones C.

PLoS One. 2015 May 1;10(5):e0124554. doi: 10.1371/journal.pone.0124554. eCollection 2015.

15.

Increased systemic exposures of artemether and dihydroartemisinin in infants under 5 kg with uncomplicated Plasmodium falciparum malaria treated with artemether-lumefantrine (Coartem®).

Tiono AB, Tinto H, Alao MJ, Meremikwu M, Tshefu A, Ogutu B, Ouedraogo A, Lingani M, Cousin M, Lefèvre G, Jain JP, Duparc S, Hamed K.

Malar J. 2015 Apr 15;14:157. doi: 10.1186/s12936-015-0682-7.

16.

Is Fc gamma receptor IIA (FcγRIIA) polymorphism associated with clinical malaria and Plasmodium falciparum specific antibody levels in children from Burkina Faso?

Cherif MK, Sanou GS, Bougouma EC, Diarra A, Ouédraogo A, Dolo A, Troye-Blomberg M, Cavanagh DR, Theisen M, Modiano D, Sirima SB, Nebié I.

Acta Trop. 2015 Feb;142:41-6. doi: 10.1016/j.actatropica.2014.09.019. Epub 2014 Oct 31.

PMID:
25447268
17.

Efficacy and safety of the mosquitocidal drug ivermectin to prevent malaria transmission after treatment: a double-blind, randomized, clinical trial.

Ouédraogo AL, Bastiaens GJ, Tiono AB, Guelbéogo WM, Kobylinski KC, Ouédraogo A, Barry A, Bougouma EC, Nebie I, Ouattara MS, Lanke KH, Fleckenstein L, Sauerwein RW, Slater HC, Churcher TS, Sirima SB, Drakeley C, Bousema T.

Clin Infect Dis. 2015 Feb 1;60(3):357-65. doi: 10.1093/cid/ciu797. Epub 2014 Nov 19. Erratum in: Clin Infect Dis. 2016 Sep 1;63(5):715.

PMID:
25414262
18.

Malaria incidence in children in South-West Burkina Faso: comparison of active and passive case detection methods.

Tiono AB, Kangoye DT, Rehman AM, Kargougou DG, Kaboré Y, Diarra A, Ouedraogo E, Nébié I, Ouédraogo A, Okech B, Milligan P, Sirima SB.

PLoS One. 2014 Jan 24;9(1):e86936. doi: 10.1371/journal.pone.0086936. eCollection 2014.

19.

Lessons learned from the use of HRP-2 based rapid diagnostic test in community-wide screening and treatment of asymptomatic carriers of Plasmodium falciparum in Burkina Faso.

Tiono AB, Ouédraogo A, Diarra A, Coulibaly S, Soulama I, Konaté AT, Barry A, Mukhopadhyay A, Sirima SB, Hamed K.

Malar J. 2014 Jan 27;13:30. doi: 10.1186/1475-2875-13-30.

20.

A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age.

Ouédraogo A, Tiono AB, Kargougou D, Yaro JB, Ouédraogo E, Kaboré Y, Kangoye D, Bougouma EC, Gansane A, Henri N, Diarra A, Sanon S, Soulama I, Konate AT, Watson NL, Brown V, Hendriks J, Pau MG, Versteege I, Wiesken E, Sadoff J, Nebie I, Sirima SB.

PLoS One. 2013 Nov 11;8(11):e78679. doi: 10.1371/journal.pone.0078679. eCollection 2013.

Supplemental Content

Loading ...
Support Center